Fig. 1: Expression and activity of JNK1 and JNK2 in pancreatic cancer cell lines. | Cancer Gene Therapy

Fig. 1: Expression and activity of JNK1 and JNK2 in pancreatic cancer cell lines.

From: c-Jun N-terminal kinase 2 suppresses pancreatic cancer growth and invasion and is opposed by c-Jun N-terminal kinase 1

Fig. 1

A JNK1 and JNK2 protein expression in seven cultured human pancreatic cancer cell lines. Western Blot was performed using JNK (sc-571) antibody primarily detecting JNK1, but cross-reactive with JNK2 (anti-JNK1) and JNK (sc-572) antibody primarily detecting JNK2, but cross-reactive with JNK1 (anti-JNK-2). β-Actin served as a loading control (third panel). Total JNK activity was determined by assessing the amount of phosphorylated c-Jun (p–c-Jun, lower panel) in a nonradioactive in vitro kinase assay (n = 1). Blots were scanned and relative JNK activity determined in relation to AsPC-1 cells. B, C Selective inhibition of JNK1 and JNK2 in PANC-1 (B) and MIA PaCa-2 (C). Cells were transfected in a stable manner with control shRNA (M-Neo-17/P-Neo-6), JNK1 shRNA (M-1–18, M-1–26/P-1–2, P-1–14), and JNK2 shRNA (M-2–12, M-2–24/P-2-2, P-2–5). The screening was performed using JNK antibodies (upper panels). β-Actin served as a loading control (third panel). C, D Total JNK activity was determined in MIA PaCa-2 by assessing the amount of phosphorylated c-Jun. A representative blot is shown in (C) and quantification of three independent experiments is shown in (D). JNK WT cells (WT and Neo clones), JNK1 KD clones, and JNK2 KD clones were analyzed together. **p < 0.001 compared to JNK WT cells.

Back to article page